Latest Actavis Stories
- Expertise in global finance, M&A, business development - DUBLIN, Nov.
DUBLIN, Nov. 5, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R.
- Increases Second Half Non-GAAP EPS Forecast to $6.60-$6.70 - DUBLIN, Nov.
DUBLIN and CHICAGO, Oct. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S.
-- Relamorelin is a Novel Peptide Ghrelin Agonist for Diabetic Gastroparesis -- DUBLIN and BOSTON, Oct.
DUBLIN, Oct. 16, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
BOSTON, Oct. 14, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc.
- A hairdresser.